How a well-planned clinical trial budget can help prevent burning bridges
A poorly negotiated budget can cause friction between sponsors and clinical trial sites, which can lead to fractured working relationships.
By
Follow @ufulti
Urtė Fultinavičiūtė is a healthcare reporter for Clinical Trials Arena. Urtė's coverage focuses on clinical data management and clinical strategy.
A poorly negotiated budget can cause friction between sponsors and clinical trial sites, which can lead to fractured working relationships.
By Urtė FultinavičiūtėClinical Trials Arena also reviews AstraZeneca's Phase I AZD-0466 cancer trial termination.
By Urtė Fultinavičiūtė, Irena Maragkou, Adam Zamecnik and William NewtonWhile DCTs aim to reduce traditional recruitment barriers, there is still work to be done to ensure diversity among…
By Urtė FultinavičiūtėIn the event the FDA limits or shutters its EUA pathway, it would throw Covid-19 vaccine and drug development…
By Urtė FultinavičiūtėClinical Trials Arena reviews publicly available ESG reports to see how CROs are looking to make improvements to their…
By Urtė FultinavičiūtėAI technology in clinical trials has the potential to speed up cohort selection and patient recruitment. However, data management…
By Urtė FultinavičiūtėSocial media buzz is in line with the pharma company’s consequential milestones and other notable events
By Urtė FultinavičiūtėPraxis in essential tremor and Altamira in vertigo are also reviewed by Clinical Trials Arena
By Urtė Fultinavičiūtė and Adam ZamecnikBristol Myers Squibb, GT Biopharma, and Gemini Therapeutics terminate early-phase trials of their respective assets.
By Urtė Fultinavičiūtė and William Newton